Nixon Peabody biotech client secures $100,000 federal innovation grant



June 03, 2015

Media Relations Director
Allison McClain
amcclain@nixonpeabody.com
617-345-1128

Jericho, NY. Nixon Peabody client Codagenix, Inc., a biotechnology startup located in Stony Brook, NY, has received a $99,811 federal grant through the U.S. Department of Agriculture Small Business Innovation Research Program (SBIR) to develop a vaccine against the virus that causes foot-and-mouth disease (FMDV), an infectious disease that affects cloven-hoofed animals.

Codagenix utilizes a breakthrough platform technology termed SAVE (synthetic attenuated virus engineering) to construct live-attenuated viral vaccines against multiple targets. All live-attenuated vaccines that are currently used in the clinic were developed using a trial-and-error-based method developed in the 1880s, predating the discovery of the DNA double helix.

Nixon Peabody served as Codagenix’s legal counsel. The team was led by partner Allan Cohen, who represents a variety of companies ranging from large public entities engaging in mergers and acquisitions to mid-sized, closely held and family-owned business, to life sciences and technology startups organizing new business ventures and raising capital.

Back to top